IRIS
SANTARPIA, Mariacarmela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.354
NA - Nord America 4.829
AS - Asia 3.531
SA - Sud America 1.320
AF - Africa 122
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 6
Totale 16.172
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.717
RU - Federazione Russa 3.417
SG - Singapore 1.458
BR - Brasile 1.130
CN - Cina 921
IE - Irlanda 672
SE - Svezia 538
IT - Italia 429
HK - Hong Kong 392
VN - Vietnam 293
GB - Regno Unito 264
PL - Polonia 215
DE - Germania 203
FR - Francia 172
FI - Finlandia 148
IN - India 107
UA - Ucraina 90
AR - Argentina 60
BD - Bangladesh 57
AT - Austria 48
ID - Indonesia 46
IQ - Iraq 44
CA - Canada 43
MX - Messico 39
EC - Ecuador 38
ZA - Sudafrica 37
TR - Turchia 33
MA - Marocco 28
ES - Italia 27
CO - Colombia 23
NL - Olanda 23
JP - Giappone 22
UZ - Uzbekistan 22
BE - Belgio 21
VE - Venezuela 19
CL - Cile 14
PK - Pakistan 14
TN - Tunisia 14
AE - Emirati Arabi Uniti 13
PY - Paraguay 13
KE - Kenya 12
PE - Perù 11
CZ - Repubblica Ceca 10
GR - Grecia 10
AZ - Azerbaigian 9
DO - Repubblica Dominicana 9
IL - Israele 9
KZ - Kazakistan 9
SA - Arabia Saudita 9
AU - Australia 8
TH - Thailandia 8
AL - Albania 7
BG - Bulgaria 7
EE - Estonia 7
LT - Lituania 7
MY - Malesia 7
PA - Panama 7
RS - Serbia 7
UY - Uruguay 7
CI - Costa d'Avorio 6
DZ - Algeria 6
EG - Egitto 6
JO - Giordania 6
KG - Kirghizistan 6
NP - Nepal 6
BO - Bolivia 5
CH - Svizzera 5
KR - Corea 5
OM - Oman 5
PH - Filippine 5
BY - Bielorussia 4
CR - Costa Rica 4
IR - Iran 4
JM - Giamaica 3
MD - Moldavia 3
SK - Slovacchia (Repubblica Slovacca) 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
AO - Angola 2
CG - Congo 2
EU - Europa 2
GE - Georgia 2
GT - Guatemala 2
HN - Honduras 2
HR - Croazia 2
KH - Cambogia 2
LB - Libano 2
LK - Sri Lanka 2
LV - Lettonia 2
MN - Mongolia 2
MT - Malta 2
NO - Norvegia 2
PT - Portogallo 2
RO - Romania 2
SN - Senegal 2
SY - Repubblica araba siriana 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BN - Brunei Darussalam 1
Totale 16.151
Salva come PNG Salva come JPEG
Città #
Moscow 1.014
Ashburn 891
Singapore 768
Dublin 672
Dallas 568
Chandler 422
Hong Kong 390
Nyköping 306
Beijing 283
Jacksonville 230
Warsaw 209
San Jose 204
The Dalles 180
Messina 179
Los Angeles 149
Lancaster 144
Princeton 132
Medford 121
Lauterbourg 107
Dearborn 98
New York 95
Cambridge 90
Des Moines 90
Ho Chi Minh City 84
Ann Arbor 77
São Paulo 76
Munich 70
Hanoi 58
Redondo Beach 58
Rio de Janeiro 47
Guangzhou 46
Tianjin 45
Turku 43
Buffalo 40
Boardman 38
Orem 37
Wilmington 37
Vienna 35
Dong Ket 32
Frankfurt am Main 29
Rome 29
Santa Clara 29
Council Bluffs 28
Jakarta 28
Shenyang 28
Jinan 27
San Mateo 26
Seattle 25
Brooklyn 23
Nuremberg 23
Montreal 22
Pune 22
Tokyo 22
Brussels 21
Johannesburg 21
Shanghai 21
Quito 20
Milan 19
Tashkent 19
Atlanta 18
Denver 18
Houston 18
Belo Horizonte 17
Düsseldorf 17
Baghdad 16
Curitiba 16
London 16
Brasília 15
Chennai 15
Porto Alegre 15
Boston 14
Haiphong 14
Mumbai 14
Nanjing 14
Salvador 14
Amsterdam 12
Biên Hòa 12
Catania 12
Da Nang 12
Helsinki 12
Woodbridge 12
Zhengzhou 12
Bexley 11
Goiânia 11
Hebei 11
Hyderabad 11
Lappeenranta 11
Poplar 11
San Francisco 11
Stockholm 11
Campinas 10
Dhaka 10
Guayaquil 10
Nairobi 10
Ningbo 10
Ribeirão Preto 10
Santiago 10
Shenzhen 10
São José do Rio Preto 10
Thái Bình 10
Totale 9.170
Salva come PNG Salva come JPEG
Nome #
Amplification and overexpression of the PSMB5 gene contributes to bortezomib resistance in retreatment of patients with multiple myeloma. 233
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy 226
Bone and lymph node metastases from occult mammary carcinoma: a case report of carcinoma of unknown primary (CUP) Syndrome 218
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations 217
Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardioprotection, Italian Society of Cardiology (SIC) 204
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy 197
Liver dysfunction in hcv infected patients with CD20-Positive B-Cell Lymphoma undergoing rituximab combination chemotherapy 191
EML4-ALK fusion gene in lung adenocarcinoma: A retrospective analysis of the outcome of cisplatin plus pemetrexed treated patients. 190
Liquid biopsy for lung cancer early detection 185
Alectinib: A selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer 184
Applications of genomics in NSCLC 183
Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer 183
Endocrine toxicity of immune checkpoint inhibitors (anti-PD-1/PD-L1) in advanced cancer 179
Early assessment of chemotherapy-related cardiovascular toxicity in patients with breast cancer 172
One-third of an archivial series of papillary thyroid cancer (Years 2007-2015) has coexistent chronic lymphocytic thyroiditis, which is associated with a more favorable Tumor-node-metastasis staging 157
Author Correction to: Prevalence of Use and Cost of Biological Drugs for Cancer Treatment: A 5-Year Picture from Southern Italy 155
Activation of viral defense signaling in cancer 153
Immunotherapeutic Advances for NSCLC 152
Targeted drugs in small-cell lung cancer 151
Association between XPD 312 single nucleotide polymorphism (SNP) and clinical outcome in stage IIIA-B non-small-cell lung cancer (NSCLC) patients (P) < 59 years (Y) treated with chemotherapy followed by surgery 151
5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer 150
Amphiregulin contained in NSCLC-exosomes induces osteoclast differentiation through the activation of EGFR pathway 147
Age-related genetic abnormalities: the Achilles’ heel for customizing therapy in elderly lung cancer patients 144
Advances in immunotherapy for treatment of lung cancer 142
Circulating biomarkers as predictors of response to immune checkpoint inhibitors in NSCLC: Are we on the right path? 141
Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do 141
Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases 141
ADCs and TCE in SCLC Therapy: The Beginning of a New Era? 140
Immune checkpoint inhibitors and neurotoxicity: a focus on diagnosis and management for a multidisciplinary approach 139
Retrospective analiysis of P-STAT6 expression as predictive marker in primary nervous system lymphoma patients assigned to high-dose methotrexate 138
Efficacy and toxicity of weekly Docetaxel as second/third line chemotherapy for advanced Non Small Cell lung cancer (NSCLC) 126
Liquid biopsy in non-small cell lung cancer: a comparison between different methodologies to detect somatic mutations 126
Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC) 124
Adaptive Resistance Mechanisms in EGFR Mutant NSCLC 124
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer 121
On the pharmacogenetics of non-small cell lung cancer treatment 121
Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario 118
A friendly approach to pesonalized treatment in lung adenocarcinoma. REVISTA COLOMBIANA DE HEMATOLOGÍA Y ONCOLOGÍA 118
Retrospective analysis of P-STAT6 expression as a predictive marker in primary nervous system lymphoma patients assigned to high-dose methotrexate 118
DNA repair and mitotic checkpoint genes as potential predictors of chemotherapy response in non-small-cell lung cancer. 116
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity 115
Myeloid-derived suppressor cells absolute counts in predicting durable response to R-CHOP in patients with follicular lymphoma. 114
Emerging drugs for non-small-cell lung cancer. 112
PIK3CA mutations in breast cancer: a potential marker 111
KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer 111
MiRNAs and Microbiota in Non-Small Cell Lung Cancer (NSCLC): Implications in Pathogenesis and Potential Role in Predicting Response to ICI Treatment 110
Comparison Study of the Safety Profile of Olaparib Versus Niraparib: Analysis of Real-World Data from EudraVigilance 109
Polymorphisms in DNA repair genes modulate survival incisplatin/gemcitabine-treated non-small-cell lung cancer patients 108
Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database 107
PIK3CA mutations and BRCA1 expression in breast cancer: potential biomarkers for chemoresistance 107
Beyond platinum treatment for NSCLC: what does the future hold? 106
Co-activation of STAT3 and YES-associated protein 1 (YAP1) pathway in EGFR-mutant NSCLC 106
Rare histotypes of epithelial biliary tract tumors: A literature review 106
How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009–2014 105
'Why is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical research' 104
Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System 103
Non-small-cell lung cancer signaling pathways, metabolism, and PD-1/PD-L1 antibodies 103
Feasibility of cell-free circulating tumor DNA testing for lung cancer 102
Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review 101
History of extensive disease small cell lung cancer treatment: Time to raise the bar? a review of the literature 101
A multicenter-retrospective study of non-small-cell lung carcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations: different subtypes of EGFR exon 19 deletion-insertions exhibit the clinical characteristics and prognosis of non-small cell lung carcinoma 100
Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: Understanding transforming growth factor-beta role 100
Temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer 100
Usefulness of predictive tests for cancer treatment 99
Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives 98
From the bench to the bed: individualizing treatment in non-small-cell lungcancer 98
Radiation recall during cemiplimab therapy for locally advanced cutaneous squamous cell carcinoma 98
Enfortumab Vedotin in metastatic bladder cancer: a case report of durable clinical efficacy in a pretreated patient 97
Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. 96
Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story? 95
Challenges and pitfalls in the management of endocrine toxicities from immune checkpoint inhibitors: a case presentation of synchronous thyrotoxicosis and primary adrenal insufficiency in a melanoma patient 95
Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer? 94
Eribulin Mesylate for the Treatment of Metastatic Hormone-refractory and Triple-negative Breast Cancer: A Multi-institutional Real-world Report on Efficacy and Safety 94
Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting System 93
Immunotherapy in NSCLC: A promising and revolutionary weapon 91
Targeting MET amplification in EGFR-mutant non-small-cell lung cancer 91
Polycythemia vera and essential thrombocytemia treated with IFN-ALPHA2a: Evidence of a significant clinical activity and molecular response. 90
Molecular characterization of synchronous sporadic colorectal carcinomas 89
Human endogenous retroviruses and cancer 89
Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints 88
Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical Need 87
PIK3CA mutations in breast cancer: A potential predictive marker 87
Melanoma: oncogenic drivers and the immune system 87
Therapeutic strategies for HER2-positive breast cancer with central nervous system involvement: a literature review and future perspectives 86
Immune Checkpoint Inhibitors and the Kidney: A Focus on Diagnosis and Management for Personalised Medicine 85
Implications of XPD312 in stage IIIA-B NSCLC 85
Other targeted drugs in melanoma 85
Personalized treatment of early-stage non-small-cell lung cancer: The challenging role of EGFR inhibitors 85
Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive 84
High-dose Radiotherapy for Oligo-progressive NSCLC Receiving EGFR Tyrosine Kinase Inhibitors: Real World Data 84
Comprehensive genomic profiling of combined small cell lung cancer 84
An exploration of the clinical progression models of osimertinib in the treatment of advanced EGFR-mutant non-small cell lung cancer 83
How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009-2013 83
Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response 83
PIK3CA mutations: a potential predictive marker in advanced breast cancer treated with antimicrotubule-based chemotherapy. 83
Predicting the outcome of chemotherapy for lung cancer. 81
Quanto sono utilizzati in Italia i farmaci biosimilari? Uno studio retrospettivo sull'uso degli agenti stimolanti l'eritropoiesi negli anni 2009-2013 81
Second-line therapy of squamous non-small cell lung cancer: an evolving landscape 80
Genistein and Curcumin Inhibit Proliferation and Invasiveness in BRAFV600E Mutant and Wild-Type Melanoma Cells: Insights into Their Anticancer Effects 79
TRANSLATIONAL RESEARCH IN GLIOBLASTOMA MULTIFORME: A REVIEW OF MOLECULAR CRITERIA FOR PATIENT SELECTION 79
Totale 12.023
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.540
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.540
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021150 0 0 0 0 0 0 0 0 0 88 19 43
2021/2022796 6 37 32 31 22 14 39 30 8 94 188 295
2022/20231.804 153 144 65 142 100 179 47 76 837 11 39 11
2023/2024551 34 75 40 41 38 132 33 28 13 29 4 84
2024/20252.932 47 31 66 145 155 110 76 646 727 204 258 467
2025/20268.470 390 562 720 713 667 1.787 1.061 1.065 1.092 413 0 0
Totale 16.592